Kevin Moran
Net Worth
Last updated:
What is Kevin Moran net worth?
The estimated net worth of Mr. Kevin Moran is at least $4,596,206 as of 6 Sep 2025. He owns shares worth $1,053,424 as insider, has earned $520,262 from insider trading and has received compensation worth at least $3,022,520 in Cardinal Health, Inc. and Vanda Pharmaceuticals Inc..
What is the salary of Kevin Moran?
Mr. Kevin Moran salary is $755,630 per year as Senior Vice President, Chief Financial Officer & Treasurer in Vanda Pharmaceuticals Inc..
What stocks does Kevin Moran currently own?
As insider, Mr. Kevin Moran owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Vanda Pharmaceuticals Inc. (VNDA) | Senior Vice President, Chief Financial Officer & Treasurer | 231,014 | $4.56 | $1,053,424 |
What does Vanda Pharmaceuticals Inc. do?
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Kevin Moran insider trading
Vanda Pharmaceuticals Inc.
Mr. Kevin Moran has made 14 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 8,902 units of VNDA stock worth $37,415 on 5 Mar 2024.
The largest trade he's ever made was exercising 16,000 units of VNDA stock on 15 Jun 2023. As of 6 Sep 2025 he still owns at least 231,014 units of VNDA stock.
Cardinal Health key executives
Cardinal Health, Inc. executives and other stock owners filed with the SEC:
- Dr. Michele A. M. Holcomb Ph.D. Chief Strategy & Bus. Devel. Officer
- Mr. Brian S. Rice Chief Information Officer, Executive Vice President & Customer Support Services
- Mr. Jason M. Hollar (52) Chief Financial Officer
- Mr. Kevin Moran Vice President of Investor Relations
- Mr. Michael C. Kaufmann (62) Chief Executive Officer & Director
- Mr. Stephen M. Mason (54) Chief Executive Officer of Medical Segment
- Mr. Victor L. Crawford (63) Chief Executive Officer of Pharmaceutical Segment
- Ms. Jessica L. Mayer (56) Chief Legal & Compliance Officer
- Ms. Ola M. Snow Chief HR Officer
- Ms. Patricia M. English Senior Vice President & Chief Accounting Officer